Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting
Pre-existing antibodies (Abs) to AAV pose a critical challenge for the translation of gene therapies. No effective approach is available to overcome pre-existing Abs. Given the complexity of Ab production, overcoming pre-existing Abs will require broad immune targeting. We generated a mouse model of...
Main Authors: | Victoria M. Velazquez, Aaron S. Meadows, Ricardo J. Pineda, Marybeth Camboni, Douglas M. McCarty, Haiyan Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300074 |
Similar Items
-
AAV genome modification for efficient AAV production
by: Walaa Asaad, et al.
Published: (2023-04-01) -
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
by: Livia S. Carvalho, et al.
Published: (2017-09-01) -
Characterization of AAV-mediated dorsal root ganglionopathy
by: Nicholas Buss, et al.
Published: (2022-03-01) -
Engineered AAV2.7m8 Serotype Shows Significantly Higher Transduction Efficiency of ARPE-19 and HEK293 Cell Lines Compared to AAV5, AAV8 and AAV9 Serotypes
by: Dzerassa Gurtsieva, et al.
Published: (2024-01-01) -
CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain
by: Sophie N. Mathiesen, et al.
Published: (2020-12-01)